tailieunhanh - Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer

Immune checkpoint inhibitor (ICI) therapy has become a viable treatment strategy in bladder cancer. However, treatment responses vary, and improved biomarkers are needed. Crucially, the characteristics of immune cells remain understudied especially in squamous diferentiated bladder cancer (sq-BLCA). Here, we quantitatively analysed the tumour-immune phenotypes of sq-BLCA and correlated them with PD-L1 expression and FGFR3 mutation status. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN